SLC13A5 Is a Novel Transcriptional Target of the Pregnane X Receptor and Sensitizes Drug-Induced Steatosis in Human Liver

Linhao Li, Haishan Li, Brandy Garzel, Hui Yang, Tatsuya Sueyoshi, Qing Li, Yan Shu, Junran Zhang, Bingfang Hu, Scott Heyward, Timothy Moeller, Wen Xie, Masahiko Negishi, and Hongbing Wang

Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland (L.L., H.L., B.G., H.Y., Q.L., Y.S., H.W.); Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental and Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina (T.S., M.N.); Department of Radiation Oncology, Case Western Reserve University, Cleveland, Ohio (J.Z.); Bioreclamation In Vitro Technologies, Baltimore, Maryland (S.H., T.M.); and Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania (B.H., W.X.)

Received December 5, 2014; accepted January 26, 2015

ABSTRACT

The solute carrier family 13 member 5 (SLC13A5) is a sodium-coupled transporter that mediates cellular uptake of citrate, which plays important roles in the synthesis of fatty acids and cholesterol. Recently, the pregnane X receptor (PXR, NR1I2), initially characterized as a xenobiotic sensor, has been functionally linked to the regulation of various physiologic processes that are associated with lipid metabolism and energy homeostasis. Here, we show that the SLC13A5 gene is a novel transcriptional target of PXR, and altered expression of SLC13A5 affects lipid accumulation in human liver cells. The prototypical PXR activator rifampicin markedly induced the mRNA and protein expression of SLC13A5 in human primary hepatocytes. Utilizing cell-based luciferase reporter assays, electrophoretic mobility shift assays, and chromatin immunoprecipitation assays, we identified and functionally characterized two enhancer modules located upstream of the SLC13A5 gene transcription start site that are associated with regulation of PXR-mediated SLC13A5 induction. Functional analysis further revealed that rifampicin can enhance lipid accumulation in human primary hepatocytes, and knockdown of SLC13A5 expression alone leads to a significant decrease of the lipid content in HepG2 cells. Overall, our results uncover SLC13A5 as a novel target gene of PXR and may contribute to drug-induced steatosis and metabolic disorders in humans.

This research is supported in part by the National Institutes of Health (NIH) [Grants R01-DR061652, R01-GM107058, and R01-GM099742] and the Intramural Research Program of the NIH [National Institute of Environmental Health Sciences] [Grant Z01ES71805-01].

dx.doi.org/10.1124/mol.114.097287.

ABBREVIATIONS: BODIPY, boron-dipyrromethene; ChIP, chromatin immunoprecipitation; DMSO, dimethylsulfoxide; EMSA, electrophoretic mobility shift assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HPH, human primary hepatocytes; hPXR, human PXR; NaDC, sodium dicarboxylate/sulfate cotransporter; PCR, polymerase chain reaction; PXR, pregnane X receptor; RIF, rifampicin; SFN, sulforaphane; siRNA, small interfering RNA; TCA, tricarboxylic acid.

Introduction

The tricarboxylic acid (TCA) cycle is central to oxidative metabolism and biosynthesis of fatty acids, glucose, and nonessential amino acids, which are pivotal to the highly coordinated energy homeostasis (Raimundo et al., 2011; Stobbe et al., 2012). The solute carrier family 13 member 5 (SLC13A5) is a newly identified sodium-coupled transporter that mediates the cellular uptake of the TCA intermediate, citrate, which functions as an important precursor in the biosynthesis of fatty acids, isoprenoids, and cholesterol (Inoue et al., 2002c; Gopal et al., 2007). Belonging to the sodium dicarboxylate/sulfate cotransporter (NaDC) family that includes the well characterized NaDC1 and NaDC3 (Pajor, 1995; Chen et al., 1998), SLC13A5 recognizes and transports various dicarboxylate and tricarboxylic TCA intermediates, with citrate holding the highest substrate affinity (Inoue et al., 2002b). Expression of SLC13A5 is most abundant in the liver, where it controls the uptake of citrate into hepatocytes from the blood stream, in which citrate circulates at a relatively high level (~150 μM) (Gopal et al., 2007). Consistent with its biologic function, immunostaining demonstrated that the SLC13A5 protein is exclusively expressed in the sinusoidal membrane of hepatocytes in the liver (Inoue et al., 2004). Notably, the blood concentration of citrate is severalfold higher than that of all other TCA intermediates combined, thus SLC13A5 may play key physiologic roles in the generation of metabolic energy by facilitating the utilization of circulating citrate, which would eventually affect pathophysiological conditions such as obesity, type 2 diabetes, and other metabolic disorders (Inoue et al., 2002b; Pajor, 2014). However, despite the postulated importance of SLC13A5 in energy metabolism, whether the expression of this uptake transporter can be perturbed under various drug exposures and how the expression of this gene is transcriptionally regulated are largely unknown.

The pregnane X receptor (PXR, NR1I2) has been characterized as one of the central components in coordinated responses to xenobiotic and endobiotic stimulation by controlling the...
transcription of numerous hepatic genes associated with xenobiotic metabolism, detoxification, and clearance (Willson and Kliewer, 2002; Tolson and Wang, 2010). In addition to the well-established role of PXR as a xenobiotic sensor, recent studies have extended the role of PXR to the regulation of various physiologic processes in control of energy homeostasis. For instance, activation of PXR is associated with upregulation of lipogenic enzymes such as steroyl CoA desaturase 1, fatty acid elongase, peroxisome proliferator-activated receptor γ, and the fatty acid transporter CD36 (Zhou et al., 2008; Wada et al., 2009). PXR can also interact with the insulin response forkhead FoxA2 and indirectly affect fatty acid β-oxidation (Nakamura et al., 2007). In cultured mouse primary hepatocytes, activation of PXR by either ligand binding or post-translational modification resulted in significant lipid accumulation (Biswas et al., 2011; Staudinger et al., 2011). On the other hand, ablation of PXR alleviates high-fat diet-induced obesity, hepatic steatosis, and insulin resistance in mice (Biswas et al., 2009; He et al., 2013). Collectively, these results suggest that activation of PXR may not only influence genes involving xenobiotic metabolism/detoxification, but also functions as a metabolic sensor affecting energy metabolism associated with various metabolic disorders.

Accumulating evidence thus far reveals that many xenobiotics, including clinically used drugs, can induce hepatic steatosis as an early manifestation of liver toxicity (Farrell, 2002). Drugs, through their modulation of peroxisome proliferator-activated receptor, liver X receptor, farnesoid X receptor, as well as PXR and its sister receptor the constitutive androstane receptor, have been shown to affect liver fat metabolism and accumulation (Kalaany and Mangelsdorf, 2006; Kallwitz et al., 2008; Konno et al., 2008). Our recent microarray results indicated that the SLC13A5 gene can be induced by rifampicin (RIF), the prototypical agonist of human PXR in human primary hepatocytes (HPH) (unpublished data). Thus, we hypothesize that inductive expression of SLC13A5 can be transcriptionally regulated by PXR, and perturbation of hepatic SLC13A5 expression may contribute to drug-induced hepatic steatosis.

In this report, we provide experimental evidence to show that the human SLC13A5 gene is a novel transcriptional target of PXR, which can be up-regulated in HPH through specific interaction of PXR with two enhancer modules located upstream of the SLC13A5 promoter. Additionally, knockdown of SLC13A5 expression is associated with decreased lipid accumulation in human liver cells. Thus, our results reveal that PXR-mediated transcription of SLC13A5 may represent a novel mechanism contributing to drug-induced hepatic steatosis.

Materials and Methods

Chemicals and Biologic Reagents. RIF and sulforaphane (SFN) were purchased from Sigma-Aldrich (St. Louis, MO). Oligonucleotide primers were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA). The Dual-Luciferase Reporter Assay System was purchased through Promega (Madison, WI). Antibodies against SLC13A5 and CYP2A4 were from Abcam (Cambridge, MA) and Millipore Corporation (Billerica, MA), respectively. β-Actin antibody was from Sigma-Aldrich. Matrigel, insulin, and ITS* (6.25 μg/ml insulin, 6.25 μg/ml transferrin, and 6.25 ng/ml selenium) were obtained from BD Biosciences (Bedford, MA). Other cell culture reagents were purchased from Life Technologies (Grand Island, NY) or Sigma-Aldrich.

Plasmid Construction and Mutagenesis. The pSG5–human PXR (hPXR) expression vector was obtained from Dr. Steven Kliewer (University of Texas Southwestern Medical Center, Dallas, TX). The SLC13A5 promoter region encompassing the sequence between +87 and +923 was polymerase chain reaction (PCR)–amplified using primers 5’-ACTAGCTAAG-GAAAGAATCACAAGGG-3’ and 5’-ATA-TATGAACTTGCAGAGGAGGAGCAC-3’, and subsequently cloned into the Nehl-HindIII sites of pGL3-basic vector generating reporter construct, namely, SLC13A5-1k. The two enhancer modules located at −22 and −1.7 kb upstream of SLC13A5 were amplified using primers 5’-CGGGCTAGCTTCCATCTGCACCCCAAGATG-3’ and 5’-ATGTTACCCTGAATATGCTTCT-3’ and 5’-GAAGGCTATAGTCAGGCTATCAGACCGGGTTCGCTC-3’. −24 to 239-bp PCR products, respectively. These two PCR products were cloned into the SLC13A5-1kb vector, creating a construct containing the SLC13A5 proximal promoter (1kb) and the distal elements, termed SLC13A5-1k/DR4-1/2. An 81-bp fragment containing three repeats of the distal DR4-1 element was cloned into the pGL3-TK plasmid, and termed SLC13A5-DR4-1-3. Site-directed mutagenesis of the elements was carried out using the QuikChange site-directed mutagenesis kit (Stratagene, CA) according to the manufacturer’s introduction. The following primers were used for mutagenesis: DR4-1mut (underlines indicate mutated bases), 5’-CTTTTCTAGGATGCATCAGGACGCT- CCCCCTTCCTCAGCGGCG-3’; DR4-2mut, 5’-GTTGGGCAATCATCACCT- GACCTGGAGGTTCCAGACGAC-3’. All constructs were verified by sequencing. The pRL-TK Renilla luciferase plasmid used to normalize firefly luciferase activities was from Promega.

HPH Cultures and Treatments. Liver tissues were obtained by medical staff after donor consent and prior approval from the Institutional Review Board at the University of Maryland School of Medicine. Hepatocytes were isolated from human liver specimens by a modification of the two-step collagenase digestion method as described previously (Hamilton et al., 2001), or were obtained from Bioreclamation In Vitro Technologies (Baltimore, MD). Hepatocytes were seeded at 1.5 × 10⁶ cells/well in six-well BioCoat plates (BD Biosciences) and cultured in the sandwich format as described previously (Faucette et al., 2007). HPH were maintained for 36 hours before treatment with 0.1% dimethylsulfoxide (DMSO), RIF (10 μM), or SFN (10 μM) for 24 or 72 hours for detection of mRNA and protein expression, respectively. For detailed concentration-response studies, hepatocytes were exposed for 24 hours to RIF (1–25 μM), whereas in time-response studies, cells were exposed to RIF (10 μM) for 2–48 hours. Culture medium was replaced on a daily basis.

Animals. Human PXR-transgenic mice with CB6F1 genetic background were established as previously described (Xie et al., 2006). Mice were kept in 12/12-hour darklight cycle and fed a standard solid diet ad libitum. hPXR-transgenic female mice received vehicle control (4% DMSO in saline) or RIF (20 mg/kg) daily via intraperitoneal injection for 5 days. Twenty-four hours after dosing, animal livers were harvested for further analysis. The use of mice in this study has complied with relevant federal guidelines and institutional policies.

Transfection in Hepatoma Cells and HPH. HepG2 cells cultured in 24-well plates were transfected with different SLC13A5 reporter constructs (60 ng/well) in the presence of the hPXR expression vector using the Fugene 6 Transfection Kit (Roche, Indianapolis, IN) following the manufacturer’s instruction. Twenty-four hours after transfection, cells were treated with vehicle control (0.1% DMSO) or RIF (10 μM) for another 24 hours. Subsequently, cell lysates were assayed for firefly activities normalized against the activities of cotransfected Renilla luciferase using the Dual-Luciferase Kit (Promega).

To characterize the function of SLC13A5 on lipid accumulation, HepG2 cells were transfected with predesigned small interfering RNA (siRNA) specific for SLC13A5 (siRNA–SLC13A5, 100 nM) or the ALLStars negative control siRNA (siRNA–NC, 100 nM) from Qiagen (Hilden, Germany), using Lipofectamine 2000 transfection reagent (Life Technologies). Seventy-two hours after transfection, intracellular lipid droplets were subjected to boron-dipyrromethene (BODIPY) staining followed by fluorescence microscopy visualization. The fluorescence intensity of BODIPY was
quantified using the National Institutes of Health ImageJ software (Bethesda, MD). In separate experiments, HPH seeded in 24-well BioCoat plates were transfected with SLC13A5-(DR4-13) construct in the presence of pRL-TK vector using Effectene reagent (Qiagen) as described previously (Faucault et al., 2007). Transfected HPH were treated with 0.1% DMSO or RIF (10 µM) for 24 hours. Cell lysates were subjected to dual-luciferase analysis as described earlier.

**Real-Time PCR Analysis.** Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and reverse transcribed using a High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA) following the manufacturers’ instructions. Real-time PCR assays were performed on an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Primers for the human SLC13A5, CYP3A4, PXR, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) include: SLC13A5, 5′-CATTGTGCCACCTCTGTAATT-3′ and 5′-AGCAAAATCGCCGCCCTAGTA-3′; CYP3A4, 5′-GTGGGGCTTTTTATGATGGTC-3′ and 5′-GGCTCCAGATTCTCACCAACAC-3′; PXR, 5′-AAGGCCAAGTTGCTAACGCAG-3′ and 5′-GGCTCTTGGGTGATCTC-3′; and GAPDH, 5′-CCCATCACCACCTTCAGGAG-3′ and 5′-GGTTCATGGATGACCTTGGC-3′.

**Western Blot Analysis.** Cell homogenate proteins were resolved on SDS–polyacrylamide gels (12%) and electrophoretically transferred onto blotting membranes. Subsequently, membranes were incubated with antibodies against SLC13A5 (diluted 1:200), CYP3A4 (diluted 1:5000), or β-actin (Sigma-Aldrich). Blots were washed and incubated with horseradish peroxidase secondary antibodies, and developed using enhanced chemiluminescence Western blotting detection reagent from GE Healthcare (Pittsburgh, PA).

**Electrophoretic Mobility Shift Assays.** Electrophoretic mobility shift assay (EMSA) was carried out as described previously (Honkakoski et al., 1998). DNA probes were labeled with [α-32P]dATP and nuclear receptor proteins were synthesized using the TNT quick-coupled in vitro transcription/translation system (Promega). A typical binding reaction (10 µl) contains 10 mM HEPES (pH 7.6), 0.5 mM dithiothreitol, 15% glycerol, 0.05% NP40, 50 mM NaCl, 2 µg of poly(dI-dC), 1 µl of in vitro translated proteins, and 4 × 10^5 cpm of labeled probe. Reaction mixtures were resolved on 5% acrylamide gels and run in 45 mM Tris–HCl buffer at a constant voltage of 70 V for 2 hours. Subsequently, gels were dried and subjected to autoradiography at −70°C.

**Chromatin Immunoprecipitation Assays.** Treated HPH were cross-linked and processed using a chromatin immunoprecipitation (ChIP) assay kit (Millipore Corporation) according to the manufacturer’s instruction. Precleared chromatin solutions were incubated with 3 µg of anti-PXR antibody (Santa Cruz Biotechnology, Dallas, TX) or normal rabbit IgG at 4°C overnight, from which immunoprecipitated samples were collected to quantify DNA using the QiAquick PCR purification kit (Qiagen). Quantitative PCR was performed as previously mentioned using the following primers: SLC13A5-DR4-1, 5′-CTCTGAGTCCTACCCCTGAAT-3′ and 5′-ATGTACCCTGACTATGCCTTC-3′; SLC13A5-DR4-2, 5′-ATGGGAGGCGGCTTTCC-3′ and 5′-GACCAGCTCTGCGCTCAGC-3′; and SLC13A5-DR4-3, 5′-GTGGGGCTTTTATGATGGTCA-3′ and 5′-ATTTGGGCCAGACGCGGTGGCTC-3′.

**Results**

**RIF Induces Expression of the SLC13A5 Gene in HPH.** As shown in Fig. 1, mRNA expression of SLC13A5 was increased by RIF in a concentration- and time-dependent manner, reaching plateaus at 10 µM and around 24 hours after treatment, respectively (Fig. 1, A and B). At the concentration typically used for PXR activation, RIF (10 µM) robustly induced SLC13A5 mRNA by 12- to 27-fold in HPH prepared from multiple liver donors (Fig. 1C). Induction of SLC13A5 protein was also observed upon RIF treatment in HPH from the same panel of donors (Fig. 1E). As expected, CYP3A4, the prototypical target gene of PXR, was also induced by RIF (Fig. 1, D and E). These results suggest that SLC13A5 is highly inducible in RIF-treated HPH, and PXR is most likely the transcription factor that mediates the induction of this citrate uptake transporter in human liver.

**Inhibition of PXR Affects Drug-Induced SLC13A5 Expression.** To further correlate contribution of PXR in the induction of SLC13A5 expression, HPH were treated with RIF in the presence or absence of SFN, a selective PXR deactivator (Zhou et al., 2007). Clearly, RIF-induced expression of SLC13A5 and CYP3A4 was significantly suppressed by SFN (Fig. 2A). In separate experiments, knockdown of human PXR expression by lentiviral–small hairpin RNA markedly attenuated RIF-mediated induction of SLC13A5 and CYP3A4 without affecting their basal expression in HPH (Fig. 2, B–D). Next, we extended our investigation to an in vivo environment, where humanized PXR–transgenic mice were treated with RIF, the selective human PXR activator, as outlined in Materials and Methods. Expression of the SLC13A5 gene was significantly induced by the activation of hPXR in the transgenic mice (Fig. 2E). Together, these results strongly support that SLC13A5 is a transcriptional target of human PXR.

**Identification of PXR-Response Elements in the Upstream of SLC13A5 Gene.** To delineate the molecular mechanism(s) by which PXR regulates SLC13A5 gene expression, we initially carried out in silico analysis of up to ~30 kb of the upstream sequence of SLC13A5 gene using the NUBIscan version 2.0 (http://www.nubiscan.unibas.ch/). Two clusters of potential PXR binding sites were identified at approximately −1.7 and −22 kb with response motifs exhibiting high sequence homology to the consensus core site of AGGTCA spaced by 4 nucleotides (DR4). As shown in Fig. 3A, three DR4 motifs in the two clusters were designated as DR4-1, DR4-2 and DR4-3. Utilizing in vitro EMSA, we found that heterodimer of PXR and the retinoid X receptor binds specifically to DR4-1 and DR4-2 at intensities equal to or exceeding that of the next-eluted-repeat (ER6) element.
from CYP3A4 promoter (Fig. 3B). Competition assays revealed that these bindings can be efficiently blocked by unlabeled DR4-1, DR4-2, or CYP3A4/ER6, but not by their respective mutants (Fig. 3C). Comparatively, DR4-1 exhibited stronger binding to PXR than DR4-2.

Furthermore, to demonstrate in vivo recruitment of PXR to the DR4-1– and DR4-2–containing regions of SLC13A5, ChIP assays were performed in HPH from two liver donors (HL98 and 99). As shown in Fig. 3, D and E, RIF treatment resulted in the recruitment of PXR to the ER6-containing region from CYP3A4 and the DR4-1–containing module of SLC13A5. On the other hand, it is interesting to note that, in contrast to the chemical-mediated recruitment of PXR to the DR4-1 region and results from EMSA, PXR failed to interact with the DR4-2 region in HPH regardless of RIF stimulation (Fig. 3E).

**Activation of PXR Increases SLC13A5 Report Activity in HepG2 and HPH.** To characterize the functional relevance of the PXR-binding elements in SLC13A5 transactivation, a number of SLC13A5 promoter constructs have been generated as depicted in Fig. 4. In HepG2 cells cotransfected with the SLC13A5-1k/DR4-1/2 luciferase and different amounts of hPXR expression vectors, corresponding luciferase activities were increased along with increasing amounts of PXR plasmid, and RIF significantly enhanced the SLC13A5 luciferase activity when PXR was cotransfected at quantities of 30 and 60 ng (Fig. 4A). In site-directed mutagenesis experiments, RIF-mediated transactivation of SLC13A5-luciferase activity through PXR was clearly abrogated by the mutation of DR4-1 but only moderately affected by the DR4-2 mutation (Fig. 4B). Additionally, we showed that the construct containing three-repeat of the distal DR4-1 exhibits stronger activation stimulated by RIF in both HepG2 cells with the cotransfection of PXR and HPH expressing endogenous PXR (Fig. 4, C and D). These data further emphasize the role of the two enhancer modules, particularly DR4-1, in PXR-mediated transactivation of SLC13A5.

**RIF Increases Lipid Accumulation in HPH.** By activating PXR, RIF changes the expression of many genes potentially associated with energy homeostasis, including SLC13A5, as observed in this study. To examine the steatogenic potential of PXR, HPH from two donors (HL66 and 70) were treated with RIF for 72 hours prior to loading of oleate, as described in Materials and Methods. Quantitative analysis of the Oil Red staining demonstrated that RIF significantly increased lipid accumulation in HPH compared to controls.
accumulation in HPH (Fig. 5A). This enhancement was also visualized under fluorescence microscopy with cellular lipids stained by BODIPY (Fig. 5B).

**Knockdown of SLC13A5 Expression Decreases Lipid Formation in HepG2 Cells.** Finally, we tested whether knockdown of SLC13A5 alone is associated with decreased lipid accumulation in HepG2 cells which maintain a relatively high level of endogenous SLC13A5 expression. As shown in Fig. 6A, expression of both mRNA and protein of SLC13A5 was significantly repressed 72 hours after transfection of siRNA-SLC13A5. BODIPY staining of the transfected cells revealed that lipid content was significantly decreased in HepG2 cells with decreased SLC13A5 expression (Fig. 6B). These data indicate that knockdown of SLC13A5 is sufficient to repress lipid formation in HepG2 cells, suggesting that perturbation of SLC13A5 may contribute to drug-induced steatotic response.

**Discussion**

SLC13A5, the sodium-coupled citrate transporter, represents the rate-limiting machinery governing the influx of citrate from circulation to the liver cells, where it plays critical roles in fatty acid synthesis, cholesterol synthesis, glycolysis, and gluconeogenesis (Inoue et al., 2002c, 2004). The potential importance of SLC13A5 in energy homeostasis has been heightened in a recent publication (Birkenfeld et al., 2011). Nevertheless, how the SLC13A5 gene is transcriptionally regulated and whether clinically used drugs could disturb the expression of this transporter are largely unknown. In this study, we have shown that SLC13A5 is a novel target of PXR, and transcription of SLC13A5 was robustly induced by RIF (a selective activator of human PXR) in HPH. We have also identified and functionally characterized two enhancer modules located upstream of the SLC13A5 gene that are associated with regulation of PXR-mediated induction of SLC13A5. Moreover, our data reveal that SLC13A5 induction was positively correlated with RIF-mediated fat accumulation in HPH, whereas knockdown of SLC13A5 significantly decreased lipid content in HepG2 cells.

As the newest member identified in the sodium dicarboxylate cotransporter family, SLC13A5 is predominantly expressed in the liver, with moderate levels in the brain and testes (Inoue et al., 2002b,c). To date, knowledge regarding the molecular control of SLC13A5 gene expression is limited. It was reported previously that the activity of SLC13A5 was significantly stimulated by therapeutic concentrations of lithium, with enhanced substrate affinity, but without affecting its expression (Inoue et al., 2003). Recently, two genome-wide DNA methylation studies revealed that SLC13A5 expression in glioblastoma and renal cancer cells was inversely associated with DNA hypermethylation in the promoter of SLC13A5, indicating that this gene might be epigenetically regulated under certain disease conditions (Etcheverry et al., 2010; Arai et al., 2012). Our results are the first to show that SLC13A5 is a highly inducible gene associated with chemical-stimulated activation of PXR in human liver. It is well known that, as a xenobiotic sensor, PXR stimulates gene expression by
binding to consensus xenobiotic response elements located in its target gene promoters (Xie et al., 2000b; Wang and LeCluyse, 2003). After computational analysis of the −30-kb upstream region of the SLC13A5 gene, two PXR response elements at −22 and −1.7 kb were identified containing DR4 motifs, with the distal DR4-1 having the most sequence homology to the distal enhancer module of CYP3A4. In vitro binding of the predicted DR4 elements with PXR/retinoid X receptor α (RXRa) heterodimer was measured using electrophoretic mobility shift assays (B and C). Oligonucleotide probes were labeled with [α-32P]dATP. Unlabeled oligonucleotides were used as cold competitor (CC). HPH from liver donors (HL98 and 99) were treated with 0.1% DMSO or RIF (10 μM). As detailed in Materials and Methods, ChIP assays were used to analyze drug-induced recruitment of PXR to the CYP3A4/ER6 (D) and DR4-1 and DR4-2 containing regions of SLC13A5 (E and F). After precipitation with IgG or PXR antibody, related ER6, DR4-1, and DR4-2 regions were amplified by PCR. CT, control (0.1% DMSO).

a number of PXR target genes contain functional distal response elements located upstream of their promoters, including CYP3A4, CYP2B6, and MDR1 (Goodwin et al., 1999; Geick et al., 2001; Wang et al., 2003). Insertion of a 247- and 239-bp fragment containing the DR4-1 and DR4-2 element, respectively, in the SLC13A5-1kb promoter has resulted in PXR-dependent activation in HepG2 cells. Notably, mutation of DR4-1 completely abolished its response to PXR, whereas DR4-2 mutant only exhibited a moderate decrease in PXR-based activation. Consistent with the binding assays, these results again demonstrate that the distal DR4-1 is critical in chemical-mediated induction of SLC13A5. Of importance, our results showed that physiologically relevant expression of endogenous nuclear receptors in HPH was able to activate the SLC13A5 promoter upon RIF treatment.

SLC13A5 is the mammalian ortholog of the “I’m not dead yet” (Indy) gene in Drosophila melanogaster (Inoue et al., 2002a). Reduced expression of Indy and its homologs has been established as a critical determinant of extending life span in...
this organism mimicking calorie restriction (Knauf et al., 2006). Given the importance of citrate in fatty acid synthesis and energy metabolism, it is reasonable to postulate that perturbation of SLC13A5 expression and/or function would influence hepatic fat accumulation and related metabolic syndromes. In line with this premise, Inoue et al. (2003) showed that lithium stimulation significantly increased SLC13A5-dependent \( \text{[14C]} \) citrate uptake and incorporation into lipids in HepG2 cells. Most recently, utilizing Slc13a5 knockout mice, Birkenfeld et al. (2011) demonstrated that mice lacking Slc13a5 expression were protected from high-fat diet–induced obesity and insulin resistance; in particular, deletion of Slc13a5 prevents lipid accumulation in the liver. In the current study, we showed that, as a potent inducer of SLC13A5, RIF enhances lipid accumulation in HPH. These results are in agreement with a previous report, in that by screening the steatogenic potential of 76 different nuclear receptor ligands, 18% of the examined ligands, including RIF, exhibited enhanced lipid accumulation in human liver cells (Moya et al., 2010). On the other hand, ketoconazole, an established inhibitor of PXR, improved the metabolic function of high-fat diet–fed mice (Huang et al., 2007; He et al., 2013). Although activation of PXR may influence the expression of multiple genes associated with lipid metabolism such as CD36, stearoyl CoA desaturase 1, and long-chain fatty acid elongase, identification of SLC13A5 as a novel target gene of PXR further highlights the multifaceted role of this receptor in energy homeostasis. The correlation between SLC13A5 and fat accumulation was further supported by our observation that knockdown of SLC13A5 expression alone decreased lipid accumulation in HepG2 cells.

In summary, we demonstrate that SLC13A5 is a highly inducible gene in human liver, and induction of this transporter is transcriptionally regulated by PXR. We have identified and characterized two distal responsive elements that are

---

**Fig. 4.** Activation of the SLC13A5 promoter by human PXR. HepG2 cells were cotransfected with SLC13A5-1k/DR4-1/2 in the presence of different amounts of hPXR expression vector (A), cotransfected with the wild-type/mutant SLC13A5 promoter constructs (B) or the SLC13A5-(DR4-1)3 with PXR for 24 hours. In separate experiments, SLC13A5-(DR4-1)3 was transfected in HPH (HL80 and 81) without exogenous expression of PXR (D). Subsequently, all transfected cells were treated with 0.1% DMSO or RIF (10 \( \mu \text{M} \)) for 24 hours. Luciferase activities were measured using the Dual-Luciferase reagent (Promega) in cell extracts according to the manufacturer’s instructions. Three independent measures from each treatment were analyzed. **\( P < 0.01 \). LUC, luciferase.
involved in PXR-mediated transactivation of the \( SLC13A5 \) gene in human hepatocytes. Meanwhile, we do recognize that, in contrast to the potent induction of the \( SLC13A5 \) mRNA observed in HPH, activation of the \( SLC13A5 \) reporter construct by RIF is relatively moderate. This discrepancy may suggest that additional unidentified PXR response module(s) may exist, which warrants further extensive investigation. Overall, the present work further expands the role of PXR

Fig. 5. RIF induces lipid accumulation in HPH. HPH from liver donors (HL66 and 70) were treated with 0.1% DMSO or RIF (10 \( \mu \)M) for 72 hours, before the cotreatment with oleate acid conjugated with 5% bovine serum albumin for another 24 hours. Lipid contents in treated cells were quantified by Oil Red O staining (A) or visualized under fluorescence microscopy by BODIPY staining (B) as detailed in Materials and Methods. Oil Red O quantifications were expressed as the mean ± S.D. (\( n = 3 \)). *\( P < 0.05 \); **\( P < 0.01 \).

Fig. 6. Knockdown of \( SLC13A5 \) expression decreases lipid formation in HepG2 cells. HepG2 cells were transfected with siRNA-\( SLC13A5 \) or siRNA–negative control (NC) using Lipofectamine 2000 reagent. Seventy-two hours after transfection, intracellular lipid droplets were subjected to BODIPY staining and fluorescence microscopy visualization as outlined in Materials and Methods. Expression of \( SLC13A5 \) mRNA and protein was analyzed using real-time PCR and Western blotting (A). BODIPY staining of lipid contents was visualized and signal density quantified using National Institutes of Health ImageJ (B). Mean ± S.D. represents results from three independent experiments. *\( P < 0.05 \); **\( P < 0.01 \).
from xenobiotic metabolism/detoxification to energy metabolism and citrate biology. Furthermore, SLC13A5 may represent a novel therapeutic target for obesity and metabolic disorders.

**Acknowledgments**

The authors thank Dr. Vadivel Ganapathy (Georgia Health Sciences University, Augusta, GA) for valuable discussion, and Dr. Zhiyong Guo (The University of Maryland School of Medicine, Baltimore, MD) for assistance in lentiviral small hairpin RNA generation.

**Authorship Contributions**

**Participated in research design:** L. Li, Xie, Sueyoshi, Negishi, Wang.

**Conducted experiments:** L. Li, H. Li, Garzel, Yang, Q. Li, Hu, Sueyoshi.

**Contributed new reagents or analytic tools:** Heyward, Moeller, Zhang, Shu.

**Performed data analysis:** L. Li, Wang.

**Wrote or contributed to the writing of the manuscript:** L. Li, Garzel, Xie, Sueyoshi, Negishi, Wang.

**References**


**Address correspondence to:** Dr. Hongbing Wang, Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201. E-mail: hwang@rx.umaryland.edu